As founder and CEO of iNFixion Bioscience, Mr. Sarnoff has led all aspects of the company since its founding in 2017, including the recruitment of a core research team and a world-class scientific advisory board, the successful execution of several NIH Phase 1 SBIR grants, launching the Company’s lab (at JLABS in San Diego), and the oversight of several scientific programs and collaborations. Infixion has also received grants from three NF foundations.
Mr. Sarnoff is an experienced entrepreneur, with over 20 years leading and consulting for multiple start-ups, including the founding of Retail Inkjet Solutions (RIS) in 2003. As CEO/Board Chairman, and later as COO, Mr. Sarnoff led RIS from 2003-2013, including: investment of $11.5M in angel/venture capital, ground-up development of complex equipment, rollout of an inkjet refill solution to 600+ retail locations (i.e. Costco) across North America and Europe, and successful prosecution of 10+ patents. Mr. Sarnoff continued as a Board Member from 2014 until the company’s eventual acquisition in 2021.
Mr. Sarnoff has a teen-age daughter with NF1, and in 2014 made a personal decision to dedicate his entrepreneurial background and skills to identifying and developing a treatment to help his daughter, and the other 2.5M people living with NF1. After several years of advocacy, fundraising, learning and investigating, including multiple false starts and significant serendipity, iNFixion was founded on the idea of developing drugs to treat NF1 at its core by eliminating NF1 protein haploinsufficiency.
Mr. Sarnoff has an international MBA from UCLA’s Anderson School of Management, and a BS in Engineering from UC San Diego. Mr. Sarnoff has lived and worked in Spain, speaks fluent Spanish, and is an inventor on 13 U.S. patents. Mr. Sarnoff has been married for 30 years, with two young adult children.